Business
America is producing more oil than ever before
Sherwood News

America’s producing more oil than ever before

Production has hit 13.4 million barrels a day, as America’s oil industry does more with less.

In 1977, President Jimmy Carter addressed the nation in a speech warning America about the potential dangers of energy dependence. Demand for oil was soaring and America “[couldn’t] substantially increase our domestic production” — forcing the country to rely on imports of oil. Now, 47 years on, Carter has had two things to celebrate in the last month: his 100th birthday and record US oil production.

Indeed, American crude-oil production rose 1.5% in August to hit a record 13.4 million barrels a day, as the top producing states of Texas and New Mexico saw output hit fresh record highs of 5.82 million and 2.09 million, respectively.

Well that was productive

Despite the number of oil rigs dropping to less than a third of the level 10 years ago and the workforce shrinking in the same period, too, oil has become one of the most productive industries in the US over the past decade. That production boom is expected to run into next year as well, with some predicting that we’ll be making an extra 600,000 barrels each day in 2025.

Indeed, the US has been consistently producing more crude oil than any nation in history for the last six years, according to figures from the Energy Information Administration, after overtaking Russia as the world’s top producer in 2018 and becoming a net exporter of oil in 2019.

US crude-oil prices saw the biggest daily drop in over a year earlier this week, and analysis from the World Bank suggests that costs will continue to fall next year as global supply looks set to outstrip demand.

Note: even though the weekly data from the US EIA is much more timely — in this case, available as recently as October 25 — it’s considerably less reliable. The monthly report is based on a much more comprehensive survey, and the trends between weekly and monthly production estimates can vary significantly, even over extended periods of time. For its part, the EIA says the monthly figures “can serve as a definitive historical benchmark” while the weekly data is more of a “near-term estimate of recent history.”

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.